BioPlus Co., Ltd
Founded in 2003 and KOSDAQ-listed in 2021, BioPlus develops HA-based bio medical devices and biopharmaceuticals using its proprietary MDM Technology platform.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureBioPlus Co., Ltd was founded in 2003 and listed on KOSDAQ in 2021, developing hyaluronic acid (HA)-based bio medical devices and biopharmaceuticals. Using its proprietary MDM Technology platform (MBMT™, DMCT™, MDAP™), the company manufactures and sells HA fillers such as SkinPlus-Hyal, Bio+Dew and the HyalDew series, the anti-adhesion agent InterBlock, the joint tissue repair material HyalSyno, the bladder tissue repair material Blad-Care, and cosmetics Kiara CE and Kiara Reju. BioPlus received its first HA filler approval from the Ministry of Food and Drug Safety at the end of 2014 and expanded sales from 2015, obtained approval for Blad-Care at the end of 2021, and operates a subsidiary in Hainan, China and a plant in Eumseong, Chungcheongbuk-do, supported by a 25-person R&D organization (3 PhDs, 15 master's, 7 bachelor's).
Products & technology
- SkinPlus-HyalTemporary improvement of facial wrinkles
- Bio+DewTemporary improvement of facial wrinkles
- HyalDew (All/Mid/Fine/Shine)Temporary improvement of facial wrinkles
- IPCHE PremiumTemporary improvement of facial wrinkles
- DeneBDermal filler for export
- InterBlockForms a physical barrier to prevent adhesion between surgical and normal tissue
- HyalSynoTemporary replacement of synovial fluid lost during knee/shoulder arthroscopic surgery
- Blad-CareTemporary improvement of cystitis symptoms by supplementing the bladder epithelial GAG layer
- Kiara CESkin hydration, regeneration promotion and texture improvement
- Kiara RejuSkin texture improvement using PDRN+HA
Regulatory approvals
data.go.kr18 Korean MFDS device approvals · 2010–2024
- MFDSGraft/prosthesis, biomaterial2024-12-11Product approval · Class 4제허 24-866 호
- MFDSGraft/prosthesis, biomaterial2023-05-10Product approval · Class 4제허 23-570 호
- MFDSGraft/prosthesis2023-03-30Product approval · Class 4제허 23-456 호
- MFDSGraft/prosthesis2023-03-30Product approval · Class 4제허 23-455 호
- MFDSGraft/prosthesis, biomaterial2021-11-15Product approval · Class 4제허 21-911 호
- MFDSGraft/prosthesis, biomaterial2021-01-26Product approval · Class 4제허 21-64 호
- MFDSGraft/prosthesis, biomaterial2021-01-05Product approval · Class 4제허 21-8 호
- MFDSGraft/prosthesis, biomaterial2020-09-04Product approval · Class 4제허 20-785 호
- MFDSGraft/prosthesis, biomaterial2020-09-04Product approval · Class 4제허 20-784 호
- MFDSGraft/prosthesis, biomaterial2019-10-29Product approval · Class 4제허 19-684 호
- MFDSGraft/prosthesis, biomaterial2019-03-18Product approval · Class 4제허 19-164 호
- MFDSDressing, adhesion barrier2019-02-01Product approval · Class 3제허 19-85 호
Show 6 more
- MFDSGraft/prosthesis, biomaterial2017-01-03Product approval · Class 4제허 17-13 호
- MFDSDressing, adhesion barrier2016-12-16Product approval · Class 3제허 16-965 호
- MFDSGraft/prosthesis, biomaterial2014-11-19Product approval · Class 4제허 14-2316 호
- MFDS탄력밴드2012-09-03Product approval · Class 1서울 수신 12-1775 호
- MFDS탄력밴드2011-08-23Product approval · Class 1서울 수신 11-1499 호
- MFDSGraft/prosthesis, biomaterial2010-08-27Product approval · Class 4제허 10-865 호
R&D and key agreements
Source: DART corporate disclosure차세대 보툴리눔 톡신 · 미용 및 만성 질환 치료 · Co-developing next-generation botulinum toxin material with reduced side effects and improved stability with Ubiprotein and ProCell Therapeutics (Mar 2022, Aug 2022)
비만/당뇨 치료제 · 비만, 당뇨 · Developing bulk production of GLP-1 class raw materials (Liraglutide, Semaglutide) with Pepgene technology (Jan 2025) and an improved dosage form using SNTel's micro-needle patch technology (Jan 2025)
아토피치료용 의약품 · 아토피 · Co-development with Centrics Bio (Jun 2023)
치매 치료제 위탁연구 · 치매 · Contract research for Centrics Bio's national dementia-treatment project, developing and optimizing the mass production process (Jun 2023)
Companies approved for the same productsPharma & CDMO
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.
Founded 2009, listed on KOSDAQ in 2019, JETEMA develops hyaluronic acid fillers, botulinum toxin biopharmaceuticals, and lifting threads.
KOSDAQ-listed medical device maker producing disposable acupuncture needles, cupping cups, and hyaluronic acid dermal fillers.
KOSDAQ-listed medical device company producing PDRN pharmaceuticals, HA fillers, and Rejuran-branded cosmetics.
KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.
KOSDAQ-listed aesthetics exporter behind HA skin booster CANDOLOV SERUM and filler brands COLENA and CANDORLOV.
KOSDAQ-listed aesthetics and CMO company behind the Elravie/Revolax hyaluronic-acid fillers and Leedstox botulinum toxin.
Founded 2000, KOSDAQ-listed 2009, Medy-Tox develops and exports botulinum toxin biopharmaceuticals including Meditoxin and Innotox.
KOSDAQ-listed medical device company manufacturing synthetic bioresorbable suture yarn and dental root canal filling materials.
KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.
Established in 2012 and listed on KOSDAQ in 2018, Osteonic manufactures implants for the CMF, Trauma, Sports Medicine, and Spine categories.
CAREGEN develops peptide-based cosmeceuticals sold in 130 countries and ophthalmic drug candidates CG-P5 and CG-T1.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition